Skye R S Fishbein, Esse M Evbuomwan, Gautam Dantas
{"title":"用工程益生菌战胜高胱氨酸尿症。","authors":"Skye R S Fishbein, Esse M Evbuomwan, Gautam Dantas","doi":"10.1016/j.chom.2024.02.008","DOIUrl":null,"url":null,"abstract":"<p><p>Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.</p>","PeriodicalId":93926,"journal":{"name":"Cell host & microbe","volume":"32 3","pages":"298-300"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conquering homocystinuria with engineered probiotics.\",\"authors\":\"Skye R S Fishbein, Esse M Evbuomwan, Gautam Dantas\",\"doi\":\"10.1016/j.chom.2024.02.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.</p>\",\"PeriodicalId\":93926,\"journal\":{\"name\":\"Cell host & microbe\",\"volume\":\"32 3\",\"pages\":\"298-300\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell host & microbe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chom.2024.02.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell host & microbe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.chom.2024.02.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Conquering homocystinuria with engineered probiotics.
Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
